Critically, SLC27A5 enhances the therapeutic efficacy of sorafenib in hepatocellular carcinoma by promoting sorafenib-induced ferroptosis through inhibition of the NRF2/GSR pathway. The gene discussed is GSR; the disease is hepatocellular carcinoma.